Clinical Trial Update: An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)

View source ↗

Summary

An observational study assessing adult participants' real-world experiences using the Risankizumab On-body Injector for Crohn's disease in the United Kingdom; s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Risankizumab On-body Injector (OBI) (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease | Status: COMPLETED